Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.65 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.65 |
| ▸ | ACE | P12821 | 5/20 | 0.63 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.62 |
| ▸ | CTSG | P08311 | 1/20 | 0.59 |
| ▸ | CMA1 | P23946 | 1/20 | 0.59 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.59 |
| ▸ | MME | P08473 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | CDC25B | P30305 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5458748 | 1.00 | ITGB3 (0.65) | ITGB3ITGA2BACEPIN1CTSG | |
| SCHEMBL4153095 | 1.00 | ITGB3 (0.65) | ITGB3ITGA2BACEPIN1CTSG | |
| SCHEMBL4147924 | 0.93 | ITGB3 (0.62) | ITGB3ITGA2BACEPIN1NAALAD2 | |
| SCHEMBL4147413 | 0.93 | ITGB3 (0.62) | ITGB3ITGA2BACEPIN1NAALAD2 | |
| SCHEMBL4147417 | 0.93 | ITGB3 (0.62) | ITGB3ITGA2BACEPIN1NAALAD2 | |
| SCHEMBL4147927 | 0.93 | ITGB3 (0.62) | ITGB3ITGA2BACEPIN1NAALAD2 | |
| SCHEMBL9440322 | 0.91 | ITGB3 (0.61) | ITGB3ITGA2BACEPIN1CTSG | |
| SCHEMBL9440326 | 0.91 | ITGB3 (0.61) | ITGB3ITGA2BACEPIN1CTSG | |
| SCHEMBL10722448 | 0.90 | CTSG (0.68) | ITGB3ITGA2BACEPIN1CTSG | |
| SCHEMBL21391851 | 0.88 | ACE (0.55) | ITGB3ITGA2BACEPIN1CTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1876169-B1 | PHENYL-CONTAINING N-ACYL AMINE AND AMINOACID DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, A PHARMACEUTICAL COMPOSITION AND THE USE THEREOF | OBSCHESTVO S OGRANICHENNOI OTVETSTENNOSTIYU PHARMENTPR (RU) | 2015-12-30 | — | — | EP | claimed |
| US-20090111874-A1 | Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU PHARMENTERPRISES (RU) | 2009-04-30 | — | — | US | claimed |
| EP-1876169-A1 | PHENYL-CONTAINING N-ACYL AMINE AND AMINOACID DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, A PHARMACEUTICAL COMPOSITION AND THE USE THEREOF | Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" (RU) | 2008-01-09 | — | — | EP | claimed |
| EP-0817795-B1 | NOVEL 4-SUBSTITUTED-3-PEPTIDYL-AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE INHIBITOR | NAEJA PHARMACEUTICAL INC (CA) | 2000-11-15 | — | — | EP | claimed |
| US-5986108-A | ENZYME INHIBITORS | SYNPHAR LABORATORIES, INC. (CA) | 1999-11-16 | — | — | US | claimed |
| EP-0817795-A1 | NOVEL 4-SUBSTITUTED-3-PEPTIDYL-AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE INHIBITOR | SYNPHAR LABORATORIES INC. (CA) | 1998-01-14 | — | — | EP | claimed |
| WO-1996032408-A1 | NOVEL 4-SUBSTITUTED-3-PEPTIDYL-AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE INHIBITOR | SYNPHAR LABORATORIES, INC. (US) | 1996-10-17 | — | — | WO | claimed |
| US-12419832-B2 | Intratumoral delivery of bortezomib | COGNOS THERAPEUTICS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12290549-B2 | Method of reducing titers of antibodies specific for a therapeutic agent | DUKE UNIVERSITY (US) | 2025-05-06 | — | — | US | disclosed |
| WO-2025034540-A1 | IMMUNOSUPPRESSIVE THERAPY TO MITIGATE ANTI-SOLUBLE ALKALINE PHOSPHATASE IMMUNE RESPONSE | ALEXION PHARMACEUTICALS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| US-8546612-B2 | Phenyl-N-acyl derivatives of amines and amino acids, a process for the preparation thereof, a pharmaceutical composition and use thereof | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU PHARMENTERPRISES (RU) | 2013-10-01 | — | — | US | disclosed |
| US-20130196050-A1 | SALTY TASTE ENHANCER | AJINOMOTO CO., INC. (JP) | 2013-08-01 | — | — | US | disclosed |
| US-20130196050-A1 | SALTY TASTE ENHANCER | AJINOMOTO CO., INC. (JP) | 2013-08-01 | — | — | US | disclosed |
| CN-1373766-A | Phosphonic acid derivatives having carboxypeptidase B inhibitory activity | MEIJI SEIKA KAISHA (JP) | 2002-10-09 | — | — | CN | disclosed |
| EP-1174434-A1 | Phosphonic acid derivative having inhibitory activity against carboxypeptidase B | MEIJI SEIKA KAISHA LTD. (JP) | 2002-01-23 | — | — | EP | disclosed |
| EP-1152004-A1 | PHOSPHONIC ACID DERIVATIVES HAVING CARBOXYPEPTIDASE B INHIBITORY ACTIVITY | MEIJI SEIKA KAISHA LTD. (JP) | 2001-11-07 | — | — | EP | disclosed |
| US-6232305-B1 | ANTICANCER AGENTS; BONE DISORDERS; ANTIARTHRITIC AGENTS; RESPIRATORY SYSTEM DISORDERS | NAEJA PHARMACEUTICAL INC. (CA) | 2001-05-15 | — | — | US | disclosed |
| EP-0961779-A1 | SUBSTITUTED AMINO BICYCLIC-$g(b)-LACTAM PENAM AND CEPHAM DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | SYNPHAR LABORATORIES INC. (CA) | 1999-12-08 | — | — | EP | disclosed |
| US-5905076-A | TREATMENT OF MUSCULAR DYSTROPHY, ARTHRITIS, MYOCARDIAL INFARCTION, ALZHEIMER'S DISEASE, BACTERIAL INFECTION, COMMON COLD, OSTEOPOROSIS OR CANCER METASTASIS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 1999-05-18 | — | — | US | disclosed |
| WO-1998032766-A1 | SUBSTITUTED AMINO BICYCLIC-β-LACTAM PENAM AND CEPHAM DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | SYNPHAR LABORATORIES INC. (US) | 1998-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196050-A1 | SALTY TASTE ENHANCER | TAS2R10, TAS2R5, TAS1R1 | ITGB3 4718/4885ITGA2B 4152/4885ACE 2441/4885 |
| US-12290549-B2 | Method of reducing titers of antibodies specific for a therapeutic agent | SNRPE, SARNP, RBM17 | ITGB3 1305/4885ITGA2B 1046/4885ACE 894/4885 |
| US-20090111874-A1 | Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof | PAH, MAOA, APEH | ITGB3 4262/4885ITGA2B 3589/4885ACE 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.